Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
N Z Vet J ; 72(3): 133-140, 2024 May.
Article in English | MEDLINE | ID: mdl-38369301

ABSTRACT

AIMS: To determine the concentration, in comparison with the maximum residue limit (MRL), of anthelmintic marker residues in the target tissues (liver and fat) of sheep treated concurrently with two oral drenches, one containing monepantel and abamectin and the other oxfendazole and levamisole. METHODS: On day 0 of the study, 12 sheep (six male and six female; 8-9-months old) were dosed according to individual body weight determined the day prior. Zolvix Plus (dual-active oral drench containing 25 g/L monepantel and 2 g/L abamectin) was administered to all animals prior to administration of Scanda (dual-active oral drench containing 80 g/L levamisole hydrochloride and 45.3 g/L oxfendazole). Six sheep (three male and three female) were slaughtered 21 and 28 days after treatment and renal fat and liver samples were collected.Using validated methods, analyses for monepantel sulfone, abamectin, levamisole and oxfendazole (expressed as total fenbendazole sulfone following conversion of the combined concentrations of oxfendazole, fenbendazole and fenbendazole sulfone) were performed on liver samples while renal fat specimens were analysed for monepantel sulfone and abamectin residues only. Detected concentrations were compared to the established MRL in sheep for each analyte determined by the Ministry for Primary Industries. RESULTS: All residues detected in samples of liver and fat collected 21 and 28 days after treatment were below the MRL for each analyte. All liver samples collected on day 21 had detectable monepantel sulfone (mean 232 (min 110, max 388) µg/kg) and oxfendazole (mean 98.7 (min 51.3, max 165) µg/kg) residues below the MRL (5,000 and 500 µg/kg, respectively). Monepantel sulfone (mean 644 (min 242, max 1,119) µg/kg; MRL 7,000 µg/kg) residues were detected in 6/6 renal fat samples. Levamisole residues were detected in 3/6 livers (mean 40.0 (min 14.3, max 78.3) µg/kg; MRL 100 µg/kg), and abamectin residues in 1/6 livers (0.795 µg/kg; MRL 25 µg/kg) and 2/6 fat samples, (mean 0.987 (min 0.514, max 1.46) µg/kg; MRL 50 µg/kg) 21 days after treatment. CONCLUSION AND CLINICAL RELEVANCE: These results suggest that concurrent administration of Zolvix Plus and Scanda to sheep is unlikely to result in an extended residue profile for any of the active ingredients, with all analytes measured being under the approved New Zealand MRL 21 days after treatment. This work was not completed in line with guidance for establishing official residue profiles, nor is it sufficient to propose a new withholding period.


Subject(s)
Aminoacetonitrile/analogs & derivatives , Anthelmintics , Benzimidazoles , Ivermectin/analogs & derivatives , Sheep Diseases , Animals , Male , Female , Sheep , Levamisole/therapeutic use , Fenbendazole/therapeutic use , Anthelmintics/therapeutic use , Sulfones/therapeutic use , Sheep Diseases/drug therapy
2.
Aust Vet J ; 92(10): 376-80, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25168341

ABSTRACT

OBJECTIVE: To demonstrate the protection of Merino sheep from flystrike by Lucilia cuprina with cyromazine or dicyclanil in an implant study and in the field. METHODS: In the implant study, sheep were treated with cyromazine or dicyclanil and implanted with 1st-stage larvae from a newly isolated field strain of L. cuprina (CYR-LS) or a reference strain (DZR50), then assessed over 3 days and compared with the implants on untreated control sheep. In the field study, weaner lambs were treated with cyromazine or dicyclanil and monitored weekly for flystrike over 18 weeks of grazing on the same farm from which the L. cuprina were isolated. RESULTS: Implant study: cyromazine (6%) provided effective protection against CYR-LS and DZR50 L. cuprina for a minimum of 13 and 10 weeks, respectively. Dicyclanil (5%) provided at least 18 weeks' protection against both strains. Field study: only 1 of 386 lambs in the cyromazine-treated group was struck in the first 14 weeks of the trial. No strikes occurred in the 198 sheep treated with dicyclanil (5%). Rainfall, temperature and flytrap data indicated consistent fly pressure during the study. CONCLUSIONS: Based on the results of these studies, there was no evidence of reduced susceptibility to cyromazine or dicyclanil and the periods of protection of sheep against L. cuprina were unaffected and consistent with the registered label claims.


Subject(s)
Diptera , Ectoparasitic Infestations/veterinary , Insecticides , Sheep Diseases/prevention & control , Sheep Diseases/parasitology , Triazines , Administration, Topical , Animals , Ectoparasitic Infestations/parasitology , Ectoparasitic Infestations/prevention & control , Juvenile Hormones , Male , Random Allocation , Sheep
3.
Aust Vet J ; 87(11): 455-62, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19857240

ABSTRACT

OBJECTIVE: To determine the efficacy of monepantel, a developmental compound from the amino-acetonitrile derivative class of anthelmintics, against field infections of gastrointestinal nematodes in sheep. PROCEDURES: Comparisons of efficacy (using standard faecal worm egg count reduction tests) and safety (on the basis of visual observations) were made in a large-scale field study in Australia, between groups of sheep treated with either an oral solution of monepantel or a registered anthelmintic. The sheep were naturally infected with the major gastrointestinal nematode genera present in Australia. RESULTS: The post-treatment efficacy results for monepantel were: at 7 days (+/-1 day) efficacy was >98%; at 14 days (+/-1 day) it was generally close to or >99%; and at 21 days (+/-1 day) efficacy was consistently >99%. A high proportion of the targeted nematode populations were confirmed as being resistant to one or more of the currently available anthelmintic classes. CONCLUSIONS: Monepantel when used under field conditions at a minimum dose rate of 2.5 mg/kg was highly effective against mixed-genus natural field infections of the major gastrointestinal nematode genera including Haemonchus, Teladorsagia (Ostertagia), Trichostrongylus, Nematodirus, Chabertia and Oesophagostomum. This result included efficacy against some populations resistant to the currently available broad-spectrum anthelmintics. Few Cooperia spp. were present to allow confirmation of efficacy against this genus. On no occasion after treatment did any commercial anthelmintic-treated groups have significantly lower faecal egg counts than the monepantel-treated groups. Monepantel was safe for the target animals and human operators when used in a field situation.


Subject(s)
Aminoacetonitrile/analogs & derivatives , Anthelmintics/therapeutic use , Helminthiasis, Animal/drug therapy , Intestinal Diseases, Parasitic/veterinary , Sheep Diseases/drug therapy , Aminoacetonitrile/therapeutic use , Animals , Australia , Drug Resistance , Feces/parasitology , Female , Intestinal Diseases, Parasitic/drug therapy , Male , Parasite Egg Count/veterinary , Sheep , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL